Castle Biosciences was founded by Derek Maetzold who believed that traditional methods to determine cancer patients’ prognosis could be improved by newly emerging techniques in molecular biology.  We continue to focus our resources on the development and marketing of our DecisionDx molecular diagnostic tests that have the ability to meaningfully impact how dermatologic cancers are diagnosed and managed.